## TSCA HEALTH & SAFETY STUDY COVER SHEET

TSCA CBI STATUS:

NONE SEHQ-0102-15052

RECEIVED

1.0 SUBMISSION TYPE		0000 1011 10 61411 10
□ 8(d) XX 8(e) □ FYI □ 4 □ OTHEI	R: Specify	2002 JAN 10 AM 11: 23
VV_Initial Submission - Follow-up Submission   I	Final Report Submission	"
Previous EPA Submission Number or Title if update or folk	ow-up: Docket Nun	nber, if any: #
TOVIOGO DI 11 DWOIME		2
continuation sheet attached		TO TOO TO HIGH ONLY
2.1 SUMMARY/ABSTRACT ATTACHED	2.2 SUBMITTER TRACKING	2.3 FOR EPA USE ONLY
(may be required for 8(e): optional for §4, 8(d) & FYI)	NUMBER OR INTERNAL ID	5
	7106 4575 1292 0337 7951	B
$X$ - YES $\square$ NO	01-2-32	
3.0 CHEMICAL/TEST SUBSTANCE IDENTITY		
Donorted I hemical	Name (specify nomenclature if other th	an CAS name):
4 o Drananadiamina	N N-dimethyl-, polymer (	NITH (N)
CAS #: 68955-01-1 1,3-Propanediamine,	rane, compd. with 3-chlo	ro-1-propene (50% 📗
	Tarie, compar water of the	4.0
quaternized)		ll ll
	$C_{\alpha}$	<b>**</b>
Purity%	COI	ntain NO CBI
X- Single Ingredient		
☐ Commercial/Tech Grade	Common Name:	11
☐ Mixture Trade Name: LR-4		% WEIGHT
<u>CAS Number</u>	<u>NAME</u>	70 11 22 22 2
Other chemical(s) present		composition des roma de un la restaura de la resta
in tested mixture		
□ continuation sheet attached		
4.0 REPORT/STUDY TITLE	Milita Dahbita Study # 8583A	8EHQ-02-15052
A Primary Eye Irritation Study in New Zealand White Rabbits, Study # 8583A  BEHU-02-15052		
		11
☐ continuation sheet attached		
5.1 STUDY/TSCATS INDEXING TERMS		hit
[CHECK ONE]	TAL EFFECTS (FF): EN	VIRONMENTAL FATE (EF):
HEALTH EFFECTS (HE): X ENVIRONMEN	(IIID Dir Doro ()	
5.2 STUDY/TSCATS INDEXING TERMS (see instruc	ROUTE OF	VEHICLE OF
STUDY SUBJECT	KOOTE OI	
TYPE: _ EIRR ORGANISM (HE, EE only) _RABE		per:
Other: Other	Julei.	
6.0 REPORT/STUDY INFORMATION Study is		l l
Laboratory Bayer Toxicology	Report/Study Date: 11/01/01	
Laboratory <u>Bayer reviewing</u>		
Source of Data/Study Sponsor (if different than submitter)		Number of pages
continuation sheet attached		<u> </u>
7.0 SUBMITTER INFORMATION	·	ll l
Janet M. Mostowy, Ph.D.		Phone: 412-777-3490
VP Product Safety & Regulatory Affairs		Phone: 412-777-3490
Bayer Corporation - 100 Bayer Road, Pit	tsburgh, PA. 15205	11
Bayer Corporation - 100 203 or 2000,	<b>3</b> ,	<b>.</b>
11		1
Technical Contact: SAME AS ABOVE		Phone: ( )
☐ continuation sheet attached		114114111111111111111111111111111111111
8.0 ADDITIONAL/OPTIONAL STUDY COMMENT	S	
This compound is a commercial product. Information w	ill be made known to appropriate person	inel and sources.
continuation sheet attached		88020000038
- Commutation shoet attached		

Submitter Signature:\_

Page\_\_1\_\_of\_\_2\_\_

for mos

Date: 11/02/01

MR 54096

PROFILE OPPLIED

## 9.0 CONTINUATION SHEET

Submitter Tracking Number/Internal ID 7106 4575 1292 0337 7951 01-2-32

## Continuation of 2.1

This study indicates that LR-430 causes severe eye irritation, thus the reporting.

## **Summary**

LR-430 was evaluated for potential primary eye irritation using six New Zealand White rabbits. Each rabbit was administered 0.1 ml of the test article to the conjunctival sac of one eye. The untreated contralateral eye of each rabbit served as a control. Treated and untreated eyes were examined and ocular irritation was scored according to the Draize method at 24, 48, and 72 hours and at 7 days after test article instillation.

The LR-430 caused severe ocular irritation in all rabbits following instillation. Ocular irritation was characterized by corneal opacity (grade 4) in all rabbits beginning at 24 hours and not changing on day 7, iritis in all rabbits (grade 2 in four rabbits and grade 1 in two rabbits), and conjunctival irritation (i.e., redness, chemosis and discharge, ranging in severity from 2 - 4) in all rabbits. All effects persisted through study termination (day 7).